WO2022110922A1 - 抗SIRPα抗体或其抗原结合片段及应用 - Google Patents
抗SIRPα抗体或其抗原结合片段及应用 Download PDFInfo
- Publication number
- WO2022110922A1 WO2022110922A1 PCT/CN2021/113416 CN2021113416W WO2022110922A1 WO 2022110922 A1 WO2022110922 A1 WO 2022110922A1 CN 2021113416 W CN2021113416 W CN 2021113416W WO 2022110922 A1 WO2022110922 A1 WO 2022110922A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- antibody
- sirpα
- antigen
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 59
- 230000027455 binding Effects 0.000 claims abstract description 70
- 239000000427 antigen Substances 0.000 claims abstract description 58
- 102000036639 antigens Human genes 0.000 claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 210000004602 germ cell Anatomy 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 241001529936 Murinae Species 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 10
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 7
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 239000000611 antibody drug conjugate Substances 0.000 claims description 6
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 claims description 5
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 claims description 5
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims description 5
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 claims description 5
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 206010073360 Appendix cancer Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000000244 kidney pelvis Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000002511 pituitary cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000014618 spinal cord cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 206010043276 Teratoma Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 abstract description 92
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 abstract description 92
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 206010057249 Phagocytosis Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000008782 phagocytosis Effects 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000003053 immunization Effects 0.000 abstract description 5
- 230000019491 signal transduction Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000003832 immune regulation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 26
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 238000001514 detection method Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 229960004641 rituximab Drugs 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 8
- 241000282567 Macaca fascicularis Species 0.000 description 8
- 101150036449 SIRPA gene Proteins 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 235000002198 Annona diversifolia Nutrition 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 101100477531 Homo sapiens SIRPA gene Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000013357 binding ELISA Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 241000282842 Lama glama Species 0.000 description 3
- 102000007614 Thrombospondin 1 Human genes 0.000 description 3
- 108010046722 Thrombospondin 1 Proteins 0.000 description 3
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100025795 Signal-regulatory protein gamma Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 2
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 241001416177 Vicugna pacos Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 108700001691 ALX148 Proteins 0.000 description 1
- 229940125979 ALX148 Drugs 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000015114 Fc-gamma receptor signaling pathway involved in phagocytosis Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108010023356 Nonmuscle Myosin Type IIA Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101710183617 Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000034720 apoptotic signaling pathway Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229920012128 methyl methacrylate acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000001845 splenic macrophage Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000000360 urethra cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to the technical field of biomedicine, in particular to an anti-SIRP ⁇ antibody or an antigen-binding fragment thereof and application thereof.
- the relationship between tumor cells and the host immune system can be divided into three different stages: elimination, equilibrium, and escape.
- the new tumor cells In the “cleared” state, the new tumor cells have strong antigenicity and are easily recognized and eliminated by the immune system; while the tumor cells that survived the clearance will enter a "balanced” state with the immune system, showing the host tumor-bearing state of survival.
- tumor cells when tumor cells accumulate genetic mutations under the selection pressure of the host immune system to a certain extent, they will break the balance and enter the final "escape” state. Tumor cells at this stage can develop a series of malignant phenotypes, turn off tumor suppressor response mechanisms, induce normal immune responses, and thus be recognized as normal cells.
- tumor cells due to the rapid unchecked growth of tumor cells, the tissue structures formed create a microenvironment that suppresses immune cells.
- tumor cells release molecules with immunosuppressive functions, such as VEGF, TGF- ⁇ , IL-10, etc., which inhibit the activation and differentiation of bone marrow dendritic cells, thereby inhibiting the adaptive immune system.
- immunosuppressive functions such as VEGF, TGF- ⁇ , IL-10, etc.
- it can induce the production of regulatory T cells (Treg) expressing CTLA-4 in peripheral blood and lymph nodes, which can inhibit other immune cells, resulting in immune tolerance of the immune system to tumors.
- CD47 protein is highly expressed on the surface of almost all tumor cells, which can interact with the signal regulatory protein ⁇ (signal regulatory protein ⁇ ) on the surface of bone marrow cells.
- protein ⁇ , SIRP ⁇ signal regulatory protein ⁇
- CD47 also known as integrin-associated protein (IAP)
- IAP integrin-associated protein
- CD47 has a molecular weight of 50kD, and its structure contains a large number of glycosylated N-terminal IgV variable domains, five highly hydrophobic transmembrane domains and a short C-terminal cytoplasmic tail, C-terminal cytoplasmic tail
- the four alternatively spliced forms of the region determine the expression of CD47 in different tissues.
- the corresponding SIRP ⁇ also known as SHPS-1, BIT or CD172a protein, is a transmembrane protein mainly expressed on myeloid cells, including macrophages, bone marrow dendritic cells, granulocytes cells, mast cells and their precursor cells.
- SIRP ⁇ consists of three extracellular Ig-like domains and four intracytoplasmic tyrosine residues that are presumed to be phosphorylation sites. After phosphorylation, SIRP ⁇ activates the downstream signaling pathway by binding to the SH2 domain of SHP-1/2 protein and activating it.
- SHP-1 and SHP-2 proteins The expression of SHP-1 and SHP-2 proteins is tissue-specific and thus SIRP ⁇ is a docked protein that recruits and activates downstream protein phosphatases in response to extracellular stimuli. Oldenborg first reported that mature red blood cells (RBC, red blood cells) protect themselves from the latter's clearance by binding to splenic macrophage SIRP ⁇ through CD47.
- RBC can also bind to monocyte SIRP ⁇ to inhibit Fc ⁇ receptor-dependent phagocytosis, which is achieved by dephosphorylation of myosin-IIA, a key molecule in phagocytosis.
- High expression of CD47 has been found in a variety of solid tumors and hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and non-Hodgkin's lymphoma. (NHL), breast cancer, bladder cancer, ovarian cancer, colon cancer, etc., the essence of which is that tumor cells evade the cellular clearance of macrophages through the regulatory mechanisms described above.
- CD47 also has effects on other biological processes through binding to other receptors or through signaling through its intracellular cytoplasmic region. Interaction of CD47 with thrombospondin-1 (TSP-1, Thrombospondin-1) or vascular endothelial growth factor receptor 2 (VEGFR-2) inhibits angiogenesis, thereby limiting tumor growth.
- TSP-1 thrombospondin-1
- Thrombospondin-1 Thrombospondin-1
- VEGFR-2 vascular endothelial growth factor receptor 2
- CD47 antibody or SIRP ⁇ -Fc recombinant protein can play a role in different mouse PDX models, and it is not compatible with common chemotherapy drugs such as cytarabine, doxorubicin, paclitaxel, cisplatin or rituximab.
- common chemotherapy drugs such as cytarabine, doxorubicin, paclitaxel, cisplatin or rituximab.
- monoclonal antibody alemtuzumab, cetuximab, and trastuzumab with good results. Sockolosky et al. reported for the first time that the combination of CD47 nanobody and PD-L1 could exhibit good antitumor effect in the Syngeneic model of melanoma B16F10 cells.
- CD47 The biological function of CD47 itself determines that the CD47 therapeutic antibody and SIRP ⁇ -Fc recombinant protein may have hematological toxicity or the risk of causing anemia, both in CD47 knockout NOD mice and in mouse models treated with CD47 antibody There are reports.
- endothelial cell CD47 has been reported to interact with SIRP ⁇ through cell adhesion to promote the transendothelial migration of T cells, and SIRP ⁇ is mainly expressed on T cells but not myeloid cells.
- SIRP ⁇ antibodies are a better choice for blocking the CD47-SIRP ⁇ signaling pathway.
- the Weissman research group of Stanford University demonstrated that the combination of the screened humanized SIRP ⁇ antibody KWAR23 and rituximab can effectively inhibit Burkitt lymphoma in SRG mice (Rag2-/-Il2r ⁇ -/-) knocking in the human SIRP ⁇ gene tumor growth, but KWAR23 alone has no obvious efficacy.
- the purpose of the present invention is to provide an anti-SIRP ⁇ antibody or its antigen-binding fragment and its application.
- the anti-SIRP ⁇ antibody or its antigen-binding fragment can bind to human SIRP ⁇ protein and block the CD47-SIRP ⁇ signaling pathway.
- an anti-SIRP ⁇ antibody or an antigen-binding fragment thereof comprising: a heavy chain variable region and a light chain variable region;
- the heavy chain variable region comprises: the amino acid sequences are respectively as shown in SEQ ID NO: VHCDR1, VHCDR2 and VHCDR3 shown in NO: 3, 4 and 5;
- the light chain variable region comprises: VLCDR1, VLCDR2 and VLCDR3 whose amino acid sequences are shown in any of the following sequences respectively;
- VLCDR The sequence of VLCDR can be found in the table below:
- variable region further comprises: a murine or human FR region.
- sequence of the FR region is of murine origin; the sequence of the heavy chain variable region is shown in SEQ ID NO: 2 or has at least 85% sequence identity with it, and the sequence of the light chain variable region is As shown in SEQ ID NO: 6 or having at least 85% sequence identity therewith.
- the human FR region includes: heavy chain FR region sequence; the heavy chain FR region sequence is derived from the combined sequence of human germline heavy chain IGHV1-18 and IGHJ2*01, including human germline heavy chain IGHV1 The FR1, FR2, FR3 regions of -18 and the FR4 region of IGHJ2*01.
- the human FR region includes: a light chain FR region sequence; the light chain FR region sequence is derived from the combined sequence of human germline light chain IGKV4-1 and IGKJ2*01, including human germline light chain IGKV4 The FR1, FR2, FR3 regions of -1 and the FR4 region of IGKJ2*01.
- the FR region sequence of the heavy chain variable region is derived from human germline, and the sequence of the heavy chain variable region is shown in SEQ ID NO: 17 or has at least 85% sequence identity therewith.
- the FR region sequence of the light chain variable region is derived from human germline, and the sequence of the light chain variable region is selected from SEQ ID NOs: 16, 18, 19, 20, 21, 22, 23, 24, 25, or have at least 85% sequence identity therewith.
- the anti-SIRP ⁇ antibody or antigen-binding fragment thereof further comprises: a heavy chain constant region selected from human IgG1, IgG2, IgG3, or IgG4 or a variant thereof; and a heavy chain constant region selected from human ⁇ , ⁇ chain or its The light chain constant region of the variant.
- the heavy chain constant region comprises: an Fc fragment or a variant thereof.
- the variant of the Fc fragment is derived from IgG1, according to EU count, including mutation sites: L234A, L235A, K338A.
- the heavy chain sequence of the anti-SIRP ⁇ antibody or antigen-binding fragment thereof is shown in SEQ ID NO: 26, or has at least 85% sequence identity therewith.
- the anti-SIRP ⁇ antibody or its antigen-binding fragment is a monoclonal antibody, a bispecific antibody, or a multi-specific antibody, or the antibody or its antigen-binding fragment is used to prepare an antibody-drug conjugate.
- the structural form of the anti-SIRP ⁇ antibody or its antigen-binding fragment is Fab, F(ab')2, Fv, or ScFv.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned anti-SIRP ⁇ antibody or antigen-binding fragment thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
- the present invention also provides a nucleic acid molecule encoding the above-mentioned anti-SIRP ⁇ antibody or an antigen-binding fragment thereof.
- the present invention also provides a vector comprising the above-mentioned nucleic acid molecule.
- the present invention also provides a host cell transformed with the above-mentioned vector.
- the present invention also provides the use of the above-mentioned anti-SIRP ⁇ antibody or antigen-binding fragment thereof in the preparation of a medicament for inhibiting or treating a disease, disorder or condition.
- the medicament is prepared by combining the anti-SIRP ⁇ antibody or antigen-binding fragment thereof with one or more other cancer therapeutic agents.
- the disease, disorder or condition includes: cancer, solid tumor, chronic infection, inflammatory disease, multiple sclerosis, autoimmune disease, neurological disease, brain injury, nerve injury, polycythemia, hemochromatosis disease, trauma, septic shock, fibrosis, atherosclerosis, obesity, type 2 diabetes, graft dysfunction or arthritis.
- the cancer is selected from anal cancer, appendix cancer, astrocytoma, basal cell carcinoma, gallbladder cancer, gastric cancer, lung cancer, bronchial cancer, bone cancer, hepatobiliary cancer, pancreatic cancer, breast cancer, liver cancer, ovary cancer, testicular cancer, kidney cancer, renal pelvis and ureter cancer, salivary gland cancer, small bowel cancer, urethra cancer, bladder cancer, head and neck cancer, spine cancer, brain cancer, cervical cancer, uterine cancer, endometrial cancer, colon cancer, colorectal cancer cancer, rectal cancer, esophageal cancer, gastrointestinal cancer, skin cancer, prostate cancer, pituitary cancer, vaginal cancer, thyroid cancer, laryngeal cancer, glioblastoma, melanoma, myelodysplastic syndrome, sarcoma, malformation Fetal tumor, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphoblastic leukemia
- the present invention also provides the use of the above-mentioned anti-SIRP ⁇ antibody or its antigen-binding fragment in the preparation of a preparation for blocking the binding of SIRP ⁇ and CD47, the preparation comprising a detection agent.
- the present invention has the following beneficial effects:
- the anti-SIRP ⁇ antibody or its antigen-binding fragment provided by the present invention can bind to human SIRP ⁇ protein, block the CD47-SIRP ⁇ signaling pathway, and is expected to be used for tumor treatment or preparation of tumor antibody drugs.
- the anti-SIRP ⁇ antibody or its antigen-binding fragment provided by the present invention can bind to all subtypes of human SIRP ⁇ protein, which is beneficial to clinical development.
- FIGS 1 to 6 show the results of Binding-ELISA.
- Figure 7 shows the results of Blocking-ELISA detection.
- FIG. 8 is the detection result of FACS detection of SIRP ⁇ antibody binding to human renal clear cell adenocarcinoma 786-O cells naturally expressing human SIRP ⁇ .
- FIGS 9 to 11 are the ADCP results of the anti-SIRP ⁇ antibody in vitro functional experiments.
- FIG. 12 is a graph showing the tumor growth curve and D18 imaging signal intensity results of tumor imaging signal values in each group.
- Figure 13 is the survival curve of each group.
- Figures 14 to 23 are graphs showing the results of ELISA detecting the binding of the antibody CHO71 of the present invention and the control antibodies 18D5 and KWAR23 to SIRP ⁇ V1/V2/V3/V4/V5/V6/V7/V8/V9/V10 subtypes.
- Figure 24 is an amino acid sequence alignment of known human SIRP alpha binding domain alleles.
- Antibody refers to an immunoglobulin (Ig) molecule that contains at least one antigen-binding site and can specifically bind to an antigen.
- an “antigen” is a substance that can induce an immune response in the body and binds specifically to an antibody. Binding of antibodies to antigens is mediated by interactions formed between them, including hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic bonds. The region on the surface of an antigen to which an antibody binds is called an "antigenic determinant” or “epitope", and in general, there are multiple determinants per antigen.
- antibody as referred to in the present invention is to be understood in its broadest sense and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, antibody fragments, antibodies comprising at least two different antigen-binding domains Multispecific antibodies (eg, bispecific antibodies).
- Antibodies also include murine antibodies, humanized antibodies, chimeric antibodies, human antibodies, and antibodies of other origins.
- Antibodies of the present invention can be derived from any animal, including but not limited to humans, non-human primates, mice, rats, cows, horses, chickens, camels, llamas (Llama), alpacas (Alpaca), Immunoglobulin molecules of llama (Guanaco), llama (Vicunas), etc.
- Antibodies may contain additional alterations such as unnatural amino acids, Fc effector function mutations and glycosylation site mutations.
- Antibodies also include post-translationally modified antibodies, fusion proteins comprising antigenic determinants of the antibody, and immunoglobulin molecules comprising any other modifications to the antigen recognition site, so long as these antibodies exhibit the desired biological activity.
- the basic structure of an antibody is a Y-shaped monomer connected by two identical heavy chains (heavy chain, H) and two identical light chains (light chain, L) through disulfide bonds.
- Each chain is composed of 2 to 5 domains (also known as functional regions) with similar sequences but different functions, containing about 110 amino acids.
- the amino acid sequence of the light chain and the heavy chain near the N-terminus of the antibody molecule changes greatly, and the formed domain is called the variable region (variable region, V region);
- the relatively constant region of the amino acid sequence near the C-terminus is called the constant region (constant region). , area C).
- VH and VL The V regions of the heavy chain and light chain are called VH and VL, respectively.
- VH and VL each have 3 regions with highly variable amino acid composition and arrangement sequence, called hypervariable region (HVR); this region forms an antigenic table.
- the spatial conformation of bit-complementary is also called complementarity determining region (CDR).
- the three CDRs of VH are represented by VHCDR1, VHCDR2, and VHCDR3, respectively, and the three CDRs of VL are represented by VLCDR1, VLCDR2, and VLCDR3, respectively.
- a total of 6 CDRs of VH and VL together form an antigen-binding site.
- the diversity of amino acids in the CDR regions is the molecular basis for the specific binding of antibodies to a large number of different antigens.
- VH and VL each have four framework regions, which are represented by FR1, FR2, FR3, and FR4, respectively.
- Each VH and VL is composed of three CDRs and four FRs, and the order from the amino terminus to the carboxyl terminus is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- human immunoglobulins can be divided into five classes: IgM, IgG, IgA, IgD, and IgE. It can also be further divided into different subclasses (isotypes), such as human IgG can be divided into IgG1, IgG2, IgG3, IgG4; IgA can be divided into IgA1 and IgA2. IgM, IgD, and IgE have not yet been found to have subclasses.
- Light chains can be classified into kappa chains and lambda chains according to their amino acid sequences.
- Antibodies of the invention can be of any class (eg, IgM, IgG, IgA, IgD, IgE) or subclass (eg, IgGl, IgG2, IgG3, IgG4, IgAl, IgA2).
- class eg, IgM, IgG, IgA, IgD, IgE
- subclass eg, IgGl, IgG2, IgG3, IgG4, IgAl, IgA2
- the constant regions of the heavy and light chains are called CH and CL, respectively.
- the heavy chain constant regions of IgG, IgA, and IgD have three domains, CH1, CH2, and CH3, and the heavy chain constant regions of IgM and IgE have four domains: CH1, CH2, CH3, and CH4.
- CH1 and CH2 are a hinge region, which is rich in proline, so it is easy to stretch and bend, and can change the distance between the two arms of the Y-shape, which is conducive to the simultaneous binding of the two arms to the epitope.
- Antigen-binding fragment refers to a Fab fragment, F(ab')2 fragment, Fv fragment, ScFv fragment, etc. having antigen-binding activity.
- Fab fragment fragment of antigen binding, Fab means an antibody fragment consisting of VL, VH, CL and CH1 domains that binds (monovalently) a single epitope.
- papain hydrolyzes IgG to form two identical Fab segments and one Fc segment; pepsin hydrolyzes IgG to form one F(ab')2 segment and several polypeptide fragments (pFc').
- Fv fragments contain antibody heavy and light chain variable regions, but no constant regions.
- Single chain variable fragment scFv single chain antibody fragment
- Single chain antibody fragment is composed of antibody heavy chain variable region and light chain variable region connected by a linker.
- Fc refers to a crystallizable fragment, which has no antigen-binding activity, and is the site of interaction of an antibody with an effector molecule or cell surface Fc receptor (FcR).
- the Fc fragment comprises the constant region polypeptides of the antibody other than the heavy chain constant region CH1. Fc fragments bind to cells with corresponding Fc receptors on their surface, resulting in different biological effects.
- ADCC effect antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity
- the Fab segment of the antibody binds to the antigenic epitope of virus-infected cells or tumor cells, and its Fc segment associates with the killer cell (NK FcR binding on the surface of cells, macrophages, etc.) mediates the direct killing of target cells by killer cells.
- ADCP is antibody-dependent cellular phagocytosis (antibody-dependent cellular phagocytosis). The mechanism of ADCP is that target cells acted on by antibodies activate the Fc ⁇ R mechanism on the surface of macrophages, induce phagocytosis, internalize target cells and be acidified and degraded by phagosomes.
- Elimination of antibody Fc function may be beneficial in certain specific situations. These situations include the use of antibodies as: (1) receptor agonists, inducing cellular signaling; (2) receptor antagonists, blocking receptor and ligand binding, inhibiting signaling; or, (3) as drug carriers to deliver drugs to target cells expressing the corresponding antigen. If the Fc function is maintained, it will cause the antibody drug to accidentally injure the cells expressing the corresponding receptor, and cause the antibody-drug conjugate to accidentally injure important immune cells when it is off-target.
- Combinations of Fc variants or mutations are not limited to the following formats (counted by EU).
- the CDR amino acid residues of the antibodies or antigen-binding fragments of the present invention conform to the known Kabat numbering convention in number and position.
- mouse-derived antibodies are a major source of antibody drugs. Due to the immunogenicity of murine antibodies, they are generally humanized.
- Murine antibodies, chimeric antibodies, and humanized antibodies are provided in the following examples.
- a "chimeric antibody” is an antibody obtained by fusing the variable region of a murine antibody with the constant region of a human antibody, and can reduce the immune response induced by the murine antibody.
- the constant region of the human antibody may be selected from heavy chain constant regions of human IgGl, IgG2, IgG3, IgG4 or variants thereof, and light chain constant regions selected from human kappa, lambda chains or variants thereof.
- Humanized antibody refers to an antibody obtained by grafting the CDR sequence of a murine antibody into the framework of a human antibody variable region, which can overcome the strong reaction induced by a chimeric antibody that carries a large amount of mouse protein components.
- Such framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences.
- human antibody variable region framework sequences can be minimally reverse-mutated or back-mutated to maintain activity.
- the humanized antibodies of the present invention also include humanized antibodies in which CDRs are further subjected to affinity maturation by phage display.
- the rationale for antibody affinity maturation in vitro is to mimic the process of antibody affinity in vivo. By constructing a random mutation library to simulate the high-frequency mutation of B cells in vivo, high-affinity antibodies can be screened.
- the medicaments provided by the present invention may contain a "therapeutically effective amount" of the antibody or antigen-binding fragment.
- a “therapeutically effective amount” refers to an amount of a therapeutic agent effective to prevent or ameliorate a particular disease, and may vary depending on factors such as the patient's disease state, age and weight, and the drug's ability to produce the desired therapeutic effect in different patients.
- Sequence identity refers to the sequence similarity between two polynucleotide sequences or between two polypeptides, and is the degree to which two polynucleotides or two polypeptides have the same bases or amino acids. "Having at least 85% sequence identity” as used herein refers to at least 85%, 90%, 95%, 97%, or 99% identity.
- Antibody-Drug Conjugates refer to binding proteins linked to one or more chemical drugs (optionally may be therapeutic or cytotoxic agents).
- Antibody drug conjugates can be obtained by linking small cytotoxic molecules (cytotoxins) and antibodies through permanent or unstable chemical linkers. ADCs selectively and consistently deliver cytotoxic drugs to tumors.
- SIRP ⁇ The gene encoding SIRP ⁇ is a polymorphic gene, and 10 SIRP ⁇ variants are known to exist in the human population. sequenced the IgV-encoding SIRP alpha domains of 37 unrelated normal Caucasians, Africans, Chinese, and Japanese from the Human HapMap Genome Project and found 10 distinct SIRP alpha IgV-encoding alleles (Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells, NATURE IMMUNOLOGY VOLUME 8 NUMBER 12 DECEMBER 2007).
- the 10 SIRP ⁇ variants are SIRP ⁇ V1/V2/V3/V4/V5/V6/V7/V8/V9/V10 subtypes, respectively.
- SIRPalpha is highly polymorphic
- the amino acid sequence alignment of the known human SIRPalpha alleles by ChiaChiM.Ho et al. showed that there are only two unique sequences at the binding interface of SIRP alpha and CD47, namely allele V1 (a2d1 ) and V2(a1d1).
- FIG. 24 amino acid sequence alignment of known human SIRP alpha binding domain alleles revealed only two variants at the CD47 contact interface: a1d1 and a2d1.
- the first line of text in Figure 24 is the amino acid sequence of the most significant human SIRP alpha allele, V1 (a2d1)
- the second line of text in Figure 1 is the amino acid sequence of the most significant human SIRP allele, V2 (a1d1).
- Black boxes indicate residues that interact with CD47, while shading indicates residues that differ from the V1 sequence.
- Janet Sim et al. identified two SIRP ⁇ variants v1 and v2 representing three allelic groups: homozygous v1/v1, homozygous v2/v2, heterozygous v1 /v2.
- the distribution and frequency of SIRP ⁇ v1 and v2 allele groups were determined in different populations and unrelated subpopulations. Among them, the distribution of v1/v2 heterozygotes in five superpopulations in Europe (EUR), America (AMR), East Asia (EAS), Africa (AFR) and South Asia (SAS) was similar, ranging from 42.0% to 47.2%. The number of v2/v2 in the East Asian population is significantly higher than that of v1/v1, and the frequency of occurrence is 42.3% and 13.3%, respectively.
- v1/v1 is higher than that of v2/v2, v1 and v2 in African, European, American, and South Asian populations
- the frequency ranges are 30.3-49.1% and 8.9-24.2%, respectively (see MABS, 2019, VOL.11, NO.6, 1036 ⁇ C1052 for references, https://doi.org/10.1080/19420862.2019.1624123).
- Aduro Biotech also studied the East Asian population with a frequency of 41.3% v2/v2 homozygotes and 34.6% v1/v1 homozygotes, which also proved that 41.3% of East Asian populations were V2/V2 homozygotes (see references for details). Voets et al. Journal for ImmunoTherapy of Cancer (2019) 7:340).
- anti-SIRP ⁇ antibodies are able to bind both SIRP ⁇ type v1 and SIRP ⁇ type v2 genes, which is crucial to facilitate clinical development.
- Example 1 Obtaining anti-SIRP ⁇ mouse antibody
- Anti-human SIRP ⁇ monoclonal antibodies were produced by immunizing mice. The experiment used Balb/c white mice, female, 6 weeks old. Breeding environment: SPF grade. After the mice were purchased, they were reared in a laboratory environment for 1 week, regulated by a 12/12 hour light/dark cycle, the temperature was 20-25°C, and the humidity was 40-60%.
- the recombinant protein QP009 (SIRP ⁇ ) 50 ⁇ g/mouse was first immunized with Freund's complete adjuvant (CFA) for two weeks, then QP009 (SIRP ⁇ ) plus incomplete Freund's adjuvant (IFA) or Alternate immunization with QP009 (SIRP ⁇ ) plus aluminum salt Alum+CpG ODN 1826, 25 ⁇ g/mouse, once a week.
- QP009 (SIRP ⁇ ) has the amino acid sequence shown below (SEQ ID NO: 1):
- mice with high antibody titers in serum were selected for splenocyte fusion. Selected mice were immunized by intraperitoneal sprint 72 hours before fusion. Hybridoma cells were obtained by fusing spleen lymphocytes with myeloma Sp2/0 cells using an optimized PEG-mediated fusion procedure. The fused hybridoma cells were resuspended in HAT complete medium (IMDM medium containing 20% FBS, 1 ⁇ HAT and 1 ⁇ OPI), and distributed in 96-well cell culture plates (1 ⁇ 10 5 cells/150 ⁇ l/ well) at 37°C, 5% CO 2 .
- HAT complete medium IMDM medium containing 20% FBS, 1 ⁇ HAT and 1 ⁇ OPI
- IMDM medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI
- HT complete medium IMDM medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI
- ELISA was performed to screen the anti-SIRP ⁇ antibody in the supernatant of the hybridoma.
- the supernatant of the hybridoma fusion well was taken, and the whole plate was screened by ELISA, and the anti-SIRP ⁇ antibody in the supernatant was detected to block the binding of SIRP ⁇ /CD47, which was the positive well of the preliminary screening.
- the positive clones were expanded and transferred to 24/6-well plates in time, and the cloned wells that were positive for the binding of cell culture supernatant to SIRP ⁇ and could block the binding of SIRP ⁇ /CD47 were detected again by ELISA, which were the positive cloned wells of anti-SIRP ⁇ antibody. .
- the positive clones were subjected to 2-3 rounds of limiting dilution to single-cell clones, and the positive single-cell strains were cryopreserved to obtain single-cell clone 71C10.
- Hybridoma-positive monoclonal cell line 71C10 was taken, mRNA was extracted, mRNA was reverse transcribed into cDNA, and cDNA was used as a template for PCR amplification. PCR-positive clones were selected and sent for sequencing.
- the heavy chain variable region sequence of 71C10 is SEQ ID NO: 2, as follows:
- VHCDR1 SEQ ID NO:3
- VHCDR2 SEQ ID NO:4
- VHCDR3 SEQ ID NO:5
- the light chain variable region sequence of 71C10 is SEQ ID NO:6, specifically as follows:
- VLCDR1 SEQ ID NO:7
- VLCDR2 SEQ ID NO:8
- VLCDR3 SEQ ID NO:9
- the murine variable region sequence of the monoclonal cell line 71C10 is fused with the human constant region gene to obtain a chimeric antibody molecule.
- the antibody light chain uses the kappa light chain constant region CL.
- different antigen sequences are designed for performance testing of antibody molecules.
- the molecular clone design of antigen and chimeric antibody is shown in Table 1 and Table 2.
- Antibodies with protein numbers of QP026027 and QP026249 were used as control antibodies, all of which used the variable region sequence of the known anti-SIRP ⁇ antibody KWAR23, with the difference in the constant region. Both QP163164 and QP163245 use the variable region of the monoclonal cell line 71C10, and the difference lies in the constant region.
- the sequences shown in the above SEQ ID NOs show the heavy and light chain sequences of each antibody molecule, respectively.
- pQD is the name of the vector with signal peptide and constant region gene (CH1-FC/CL) fragment, among which, pQDH is used for the connection and expression of heavy chain variable region, with signal peptide and constant region gene (CH1-FC) fragment ; pQDK is used for ligation and expression of light chain variable region, with signal peptide and constant region gene (CL) fragment.
- H indicates heavy chain and "L” indicates light chain.
- (IgG4) means that the heavy chain adopts the constant region of human IgG4. If not marked with "(IgG4)", the constant region of human IgG1 is used by default.
- 180122VH represents the heavy chain variable region derived from the monoclonal cell line 71C10
- 180122VL represents the light chain variable region derived from the monoclonal cell line 71C10.
- pQDH-KWAR23-H means that the control sequence KWAR23 is fused to a pQDH vector with a signal peptide and a fragment of a constant region gene (CH1-FC), using the constant region of human IgG1.
- pQDH-180122VH means that the heavy chain variable region sequence 180122VH is fused to the pQDH vector, using the constant region of human IgG1.
- the double underlined part is the constant region sequence.
- the double underlined part is the constant region sequence.
- QP098 is cynomolgus monkey SIRP ⁇ sequence (uniprot database sequence number I7G9Z7)
- QP100 is cynomolgus monkey SIRP ⁇ sequence (uniprot database sequence number G7PGS8)
- QP271 is rhesus monkey SIRP ⁇ sequence, obtained by the inventor by sequencing monkey PBMC
- QP273 The cynomolgus monkey SIRP ⁇ sequence was obtained by the inventors by sequencing monkey PBMC.
- the 293E cell culture density was maintained between (0.2-3) ⁇ 10 6 /ml, and the maintenance phase medium (GIBCO Freestyle 293 expression medium) was cultured.
- the cells to be transfected were centrifuged to change the medium, and the cell density was adjusted to ( 0.5-0.8) x 10 6 /ml.
- the density of 293E cells was (1-1.5) x 106 /ml.
- Prepare plasmid and transfection reagent PEI the amount of plasmid to be transfected is 100 ⁇ g/100ml cells, and the mass ratio of PEI and plasmid is 2:1. Mix the plasmid and PEI, let stand for 15min, not more than 20min.
- the plasmid and PEI mixture was slowly added to the 293E cells, cultured in a shaker at 8% CO 2 , 120 rpm, and 37° C. On the fifth day of transfection, the cell supernatant was collected by centrifugation at 4700 rpm in a horizontal centrifuge for 20 min.
- Protein A affinity chromatography purification use the equilibrium solution to pass through the column, at least 3CV, the actual volume is 20ml, to ensure that the pH and conductivity of the solution flowing out of the final instrument are consistent with the equilibrium solution, the flow rate is 1ml/min; the supernatant of the culture medium after centrifugation is passed through the column , load 40ml, flow rate 0.33ml/min; pass through the column with equilibrium solution, at least 3CV, actual volume 20ml, ensure that the pH and conductivity of the solution flowing out of the final instrument are consistent with the equilibrium solution, flow rate 0.33ml/min; Column, when the UV280 rises to 15mAU, the elution peak (PAC-EP) starts to be collected, and when the UV280 drops to 15mAU, the collection is stopped, and the flow rate is 1 ml/min. After sample collection, PAC-EP was adjusted to neutrality with pH adjustment solution.
- PAC-EP elution peak
- the affinity of anti-SIRP ⁇ chimeric antibody QP163164 to human SIRP ⁇ type V1 (protein number QP094) and human SIRP ⁇ type V2 (protein number QP096) was determined by Biacore T200 (GE). Tables 3 and 4 show the detection results of QP163164 and QP026027. The results showed that the SIRP ⁇ chimeric antibody QP163164 had an affinity KD of 5.27E-10M for binding to human SIRP ⁇ V1, and a KD value of 6.78E-10M for binding to human SIRP ⁇ V2. The binding affinity of human SIRP ⁇ V1 and human SIRP ⁇ V2 was significantly better than that of the control antibody KWAR23 (QP026027).
- variable region sequence is formed in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Then select some important amino acid residues for back mutation combination. The amino acid residues are identified and annotated by the Kabat numbering system.
- the heavy chain FR region sequence is derived from the combined sequence of human germline heavy chain IGHV1-18 and IGHJ2*01, which comprises the FR1, FR2, FR3 regions of human germline heavy chain IGHV1-18 and IGHJ2*01 FR4 region.
- the light chain FR region sequence is derived from the combined sequence of human germline light chain IGKV4-1 and IGKJ2*01, which includes the FR1, FR2, FR3 regions of human germline light chain IGKV4-1 and the FR4 region of IGKJ2*01.
- Design primers PCR to build each humanized antibody VH/VK gene fragment, and then carry out homologous recombination with the expression vector pQD (with signal peptide and constant region gene (CH1-FC/CL) fragment) to construct the full-length antibody expression vector VH- CH1-FC-pQD/VK-CL-pQD.
- pQD signal peptide and constant region gene
- the expression vector pQD was constructed and digested, and the expression vector pQD was designed and constructed by using some special restriction enzymes, such as the BsmBI recognition sequence and the different characteristics of the restriction site. BsmBI digested the vector, and the gel was cut for recovery.
- heavy chain expression vector pQD-VH-CH1-FC and light chain expression vector pQD-VL-CL heavy chain variable region VH gene fragment and BsmBI digested vector pQD (with signal peptide and heavy chain constant region (CH1 -FC) fragment) according to 3:1 ratio; light chain variable region VL gene fragment and BsmBI digested vector pQD (with signal peptide and light chain constant region (CL) fragment) according to 3:1 ratio;
- the mixtures were transferred into DH5a competent cells, ice bathed at 0°C for 30 min, heat-shocked at 42°C for 90s, added with 5 volumes of LB medium, incubated at 37°C for 45min, coated with LB-Amp plates, incubated at 37°C overnight, and single clones were picked. The clones of interest were obtained by sequencing.
- the table below shows specific information on the humanized design of QP163164.
- the protein expression number is QP256253.
- the light chain of the antibody adopts the constant region CL of the light chain of kappa
- the heavy chain of the antibody adopts the constant region of human IgG4 (for the specific sequence of the constant region, please refer to Example 2).
- the humanized design light and heavy chain variable region sequences are not limited to the sequences shown in the table below.
- the light chain variable region of QP256253 is encoded by plasmid accession QD253.
- the specific sequence of light chain variable region sequence SEQ ID NO:16 is:
- the heavy chain variable region of QP256253 is encoded by plasmid accession QD256.
- the specific sequence of the heavy chain variable region sequence SEQ ID NO: 17 is:
- the 293E cell culture density was maintained between (0.2-3) ⁇ 10 6 /ml, and the maintenance phase medium (GIBCO Freestyle 293 expression medium) was cultured.
- the cells to be transfected were centrifuged to change the medium, and the cell density was adjusted to ( 0.5-0.8) x 10 6 /ml.
- the density of 293E cells was (1-1.5) x 106 /ml.
- Prepare plasmid and transfection reagent PEI the amount of plasmid to be transfected is 100 ⁇ g/100ml cells, and the mass ratio of PEI and plasmid is 2:1. Mix the plasmid and PEI, let stand for 15min, not more than 20min.
- the plasmid and PEI mixture was slowly added to the 293E cells, cultured in a shaker at 8% CO 2 , 120 rpm, and 37° C. On the fifth day of transfection, the cell supernatant was collected by centrifugation at 4700 rpm in a horizontal centrifuge for 20 min.
- Protein A affinity chromatography purification use the equilibrium solution to pass through the column, at least 3CV, the actual volume is 20ml, to ensure that the pH and conductivity of the solution flowing out of the final instrument are consistent with the equilibrium solution, the flow rate is 1ml/min; the supernatant of the culture medium after centrifugation is passed through the column , load 40ml, flow rate 0.33ml/min; pass through the column with equilibrium solution, at least 3CV, actual volume 20ml, ensure that the pH and conductivity of the solution flowing out of the final instrument are consistent with the equilibrium solution, flow rate 0.33ml/min; Column, when the UV280 rises to 15mAU, the elution peak (PAC-EP) starts to be collected, and when the UV280 drops to 15mAU, the collection is stopped, and the flow rate is 1 ml/min. After sample collection, PAC-EP was adjusted to neutrality with pH adjustment solution.
- PAC-EP elution peak
- Binding-ELISA experimental method QP094 (SIRP ⁇ V1-flag-his), QP096 (SIRP ⁇ V2-Flag-his), QP100 (cynoSIRP ⁇ -flag-his) were coated with 0.5 ⁇ g/ml, 50 ⁇ l/well, 4 degrees overnight.
- the affinity of the humanized antibody to human SIRP ⁇ V1, human SIRP ⁇ V2 and cynomolgus monkey SIRP ⁇ was determined by biacore as shown in Table 6 below.
- the results show that the anti-SIRP ⁇ humanized antibody QP256253 binds to human SIRP ⁇ V1 with an affinity KD of 3.36E-10M, and it binds to human SIRP ⁇ type V2 affinity KD value is 3.19E-10M.
- the humanized QP256253 was constructed into a phagemid vector in scFv mode (VH-3 GGGGS-VL), respectively, as the wild-type sequence (ie, as the original or starting sequence, the mutant sequence obtained by affinity maturation screening).
- VH, (GGGGS)3 linker, VL were spliced by over-lap PCR, and ligated into phagemid vector using NcoI and NotI restriction sites.
- the codons in the mutant region have 50% wild-type codons and 50% NNK (the reverse primer is MNN), introducing mutations in all CDR regions to construct a mutant library.
- the PCR fragment was digested with NcoI and NotI, ligated into a phagemid vector, and finally electrotransformed into E. coli TG1. Each codon-based primer creates an independent library.
- liquid-phase panning was performed using biotinylated QP098 (cynoSIRP ⁇ (ECD)) antigen and streptavidin magnetic beads, and each round of screening was relative to the previous one. All rounds reduce antigen concentration.
- 250 clones were picked for phage ELISA to detect binding activity, and positive clones were sequenced.
- the non-redundant sequences were converted into full-length IG (CH1-CH2-CH3 of hIgG4 for the heavy chain constant region; ⁇ light chain CL for the light chain constant region) for lactation. Animal cell expression.
- Full-length IG protein was obtained after affinity purification.
- the specific sequence is shown in the table below.
- the light chain of the antibody adopts the constant region CL of the light chain of kappa
- the heavy chain of the antibody adopts the constant region of human IgG4 (for the specific sequence of the constant region, please refer to Example 2).
- the nomenclature of protein numbers is a combination of heavy chain plasmid number and light chain plasmid number.
- its heavy chain plasmid number is QD256
- its light chain plasmid number is QD279.
- the sequences indicated by the SEQ ID NOs in the table are the heavy chain variable region or light chain variable region sequences of different antibodies.
- the specific sequence of the light chain variable region is as follows:
- Binding-ELISA experimental method coat QP094 (SIRP ⁇ V1-flag-his), QP096 (SIRP ⁇ V2-Flag-his), QP098 (cynoSIRP ⁇ -flag-his), QP100 (cynoSIRP ⁇ -flag-his) 0.5 ⁇ g/ml, 50 ⁇ l respectively /hole, 4 degrees overnight.
- Blocking-ELISA experimental method coat QP001.2 2 ⁇ g/ml, 4 degrees overnight, wash 3 times with PBS, block 5% milk 250 ⁇ l/well, incubate Biotin-QP002 0.05 ⁇ g/ml+Abs 50 ⁇ g/ml 1:1 mixing, 25 Incubate for 1 h with HRP-Strepavidin (1:5000). The results are shown in Figure 7.
- the affinity of the anti-SIRP ⁇ antibody with human SIRP ⁇ V1, human SIRP ⁇ V2 and cynomolgus monkey SIRP ⁇ was determined by biacore, and some of the results are shown in Table 10.
- the anti-SIRP ⁇ antibodies QP2561589, QP2561586, QP2561581, QP256279, and QP2561770 all bound to human SIRP ⁇ type V1 and human SIRP ⁇ type V2.
- QP2561589, QP2561586, QP256279, QP2561770, and QP256253 all bind to different cynomolgus monkey and rhesus monkey SIRP ⁇ proteins.
- Example 5 FACS detection of anti-SIRP ⁇ antibody binding to human renal clear cell adenocarcinoma 786-O cells naturally expressing human SIRP ⁇
- the anti-SIRP ⁇ antibody is made into different IgG subtypes, and the molecular cloning design is as follows:
- the nomenclature of protein numbers is a combination of heavy chain plasmid number and light chain plasmid number.
- the sequences shown in the SEQ ID NOs of the heavy chains are the heavy chain sequences of antibodies of different subtypes.
- the sequences shown in the SEQ ID NOs of the light chains are the light chain or light chain variable region sequences of antibodies of different subtypes.
- the sequence of the light chain variable region of QP32700279 is shown in SEQ ID NO:18.
- Macrophage Preparation of macrophages (Macrophage): revive PBMC, separate monocytes with EasySep TM Human Monocyte Isolation Kit (Stemcell-19359), add Human Recombinant M-CSF (final concentration of 50ng/mL), mix well The cells were cultured at 37°C for 6 days to induce Macrophage; the cells were collected and counted for use. CFSE labeled Raji cells.
- Example 7 Evaluation of the inhibitory effect of anti-SIRP ⁇ antibody on Raji-Luc tumor growth by QP32700279 in the B-NDG-hSIRP ⁇ mouse model
- the Raji-Luc tumor model was intravenously inoculated with B-NDG-hSIRP ⁇ to evaluate the growth inhibitory effect of SIRP ⁇ antibody and Rituximab on tumor.
- Raji-Luc cells were cultured in RPMI1640 medium containing 10% fetal bovine serum.
- Raji-Luc cells resuspended in PBS were inoculated into the tail vein of B-NDG-hSIPRa mice at a concentration of 5 ⁇ 10 5 cells/0.2 mL and a volume of 0.2 mL/cell.
- a small animal imager was used to measure the tumor imaging signal value.
- the administration volume is calculated according to the body weight of the experimental animal at 10 ⁇ L/g;
- Q3D means dosing once every 3 days
- Q2W means dosing once every 2 weeks.
- the day of group administration was counted as D0, and as of D18, the tumor growth curve and D18 imaging signal intensity data of each group of tumor imaging signal values are shown in Figure 12 and the following table:
- mice Due to the characteristics of the model, the mice will appear abnormal movement or paralysis in the later stage of the experiment. At this time, the mice are euthanized and the survival curve is recorded. By the end of the G1 group of mice all dead (D25), the survival curves of each group are shown in Figure 13
- Example 8 ELISA detection of anti-SIRP ⁇ antibody binding to all subtypes of human SIRP ⁇
- SIRP alpha Signal Regulatory Protein
- the SIRP ⁇ antibody QP256279 was stably expressed in CHOS cells, and the CHOS stably expressed protein was numbered as CHO71.
- the SIRP ⁇ antibody CHO71 of the present invention binds to all subtypes of SIRP ⁇ V1/V2/V3/V4/V5/V6/V7/V8/V9/V10.
- OSE's SIRPa antibody 18D5 does not bind SIRPa V2/V3/V7/V8/V10.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
conc.(μg/ml) | QP094 | QP096 | QP098 | QP100 | QP271 | QP273 |
QP2561589 | 0.001366 | 0.001171 | 0.001598 | 0.002009 | 0.0009365 | 0.001429 |
QP256291 | 0.001859 | 0.001429 | 0.00157 | 0.001178 | 0.001173 | 0.001618 |
QP2561586 | 0.001046 | 0.001108 | 0.001199 | 0.001235 | 0.0009672 | 0.001027 |
QP2561581 | 0.001075 | 0.0008623 | 0.0009179 | 0.0007578 | 0.0005554 | 0.0009209 |
QP2561594 | 0.001115 | 0.001055 | 0.001134 | 0.0009833 | 0.0008066 | 0.002348 |
QP256279 | 0.0006508 | 0.0006239 | 0.000619 | 0.0005584 | 0.0006008 | 0.0007207 |
QP2561770 | 0.001615 | 0.001363 | 0.001302 | 0.001005 | 0.001207 | 0.001675 |
QP2561771 | 0.001145 | 0.001127 | 0.001082 | 0.001128 | 0.001127 | 0.001217 |
QP256253 | 0.001189 | 0.001185 | 0.001255 | 0.00172 | 0.0009472 | 0.001514 |
QP163245 | 0.001106 | 0.001235 | 0.001526 | 0.001166 | 0.0008822 | 0.0016 |
QP026249 | 0.005285 | 0.003311 | 0.02366 | 0.001925 | 0.00193 | 0.002028 |
Claims (14)
- 一种抗SIRPα抗体或其抗原结合片段,其特征在于,包含:重链可变区和轻链可变区;所述重链可变区包含:氨基酸序列分别如SEQ ID NO:3、4、5所示的VHCDR1、VHCDR2和VHCDR3;所述轻链可变区包含:氨基酸序列分别如以下任意一组序列所示的VLCDR1、VLCDR2和VLCDR3;(1)SEQ ID NO:37、38、9;(2)SEQ ID NO:39、38、9;(3)SEQ ID NO:7、40、9;(4)SEQ ID NO:7、8、41;(5)SEQ ID NO:7、8、42;(6)SEQ ID NO:7、8、43;(7)SEQ ID NO:37、38、41;(8)SEQ ID NO:44、38、41;(9)SEQ ID NO:7、8、9。
- 根据权利要求1所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述可变区还包含:鼠源或人源FR区。
- 根据权利要求2所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述FR区的序列为鼠源;所述重链可变区的序列如SEQ ID NO:2所示或与其具有至少85%序列同一性,所述轻链可变区的序列如SEQ ID NO:6所示或与其具有至少85%序列同一性。
- 根据权利要求2所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述人源FR区包括:重链FR区序列和轻链FR区序列;所述重链FR区序列来源于人种系重链IGHV1-18及IGHJ2*01的组合序列,包括人种系重链IGHV1-18的FR1、FR2、FR3区和IGHJ2*01的FR4区;所述轻链FR区序列来源于人种系轻链IGKV4-1及IGKJ2*01的组合序列,包括人种系轻链IGKV4-1的FR1、FR2、FR3区和IGKJ2*01的FR4区。
- 根据权利要求2所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述重链可变区的序列如SEQ ID NO:17所示或与其具有至少85%序列同一性;所述轻链可变区的序列选自SEQ ID NO:16、18、19、20、21、22、23、24、25中任意一项,或与其具有至少85%序列同一性。
- 根据权利要求1所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述抗SIRPα抗 体或其抗原结合片段还包含:选自人源IgG1、IgG2、IgG3、或IgG4或其变体的重链恒定区;以及选自人源κ、λ链或其变体的轻链恒定区。
- 根据权利要求6所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述重链恒定区包含:Fc片段或其变体;所述Fc片段的变体来源于IgG1,根据EU计数,包括突变位点:L234A、L235A、K338A。
- 根据权利要求1所述的抗SIRPα抗体或其抗原结合片段,其特征在于,所述抗SIRPα抗体或其抗原结合片段的重链序列如SEQ ID NO:26所示,或与其具有至少85%序列同一性。
- 根据权利要求1所述的抗SIRPα抗体或其抗原结合片段,其特征在于,其为单克隆抗体、双特异抗体、或多特异抗体,或者,所述的抗体或其抗原结合片段用于制备抗体药物偶联物。
- 根据权利要求1所述的抗SIRPα抗体或其抗原结合片段,其特征在于,其结构形式为Fab、F(ab’)2、Fv、或ScFv。
- 一种药物组合物,其含有权利要求1至10中任意一项所述的抗SIRPα抗体或其抗原结合片段,以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
- 一种核酸分子,其编码权利要求1至10中任意一项所述的抗SIRPα抗体或其抗原结合片段。
- 权利要求1至10中任意一项所述的抗SIRPα抗体或其抗原结合片段在制备用于抑制或治疗疾病、病症或状况的药物中的用途。
- 根据权利要求13所述的用途,其特征在于,所述疾病、病症或状况包括:癌症、实体瘤、慢性感染、炎性疾病、多发性硬化、自身免疫性疾病、神经系统疾病、脑损伤、神经损伤、红细胞增多症、血色素沉着病、创伤、感染性休克、纤维化、动脉粥样硬化、肥胖症、II型糖尿病、移植功能障碍或关节炎;所述癌症选自肛门癌、阑尾癌、星形细胞瘤、基底细胞癌、胆囊癌、胃癌、肺癌、支气管癌、骨癌、肝胆管癌、胰腺癌、乳腺癌、肝癌、卵巢癌、睾丸癌、肾癌、肾盂和输尿管癌、唾液腺癌、小肠癌、尿道癌、膀胱癌、头颈癌、脊柱癌、脑癌、宫颈癌、子宫癌、子宫内膜癌、结肠癌、结直肠癌、直肠癌、食道癌、胃肠道癌、皮肤癌、前列腺癌、垂体癌、阴道癌、甲状腺癌、喉癌、胶质母细胞瘤、黑素瘤、骨髓增生异常综合征、肉瘤、畸胎瘤、慢性淋巴细胞白血病(CLL)、慢性髓性白血病(CML)、急性淋巴细胞白血病(ALL)、急性髓性白血病(AML)、霍奇金淋巴瘤、非霍奇金淋巴瘤、多发性骨髓瘤、T或B细胞淋巴瘤、胃肠道间质瘤、软组织肿瘤、肝细胞癌或腺癌。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023532562A JP2024501134A (ja) | 2020-11-30 | 2021-08-19 | 抗SIRPα抗体またはその抗原結合断片および適用 |
US18/254,941 US20240018255A1 (en) | 2020-11-30 | 2021-08-19 | ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF |
EP21896427.8A EP4253416A1 (en) | 2020-11-30 | 2021-08-19 | Anti-sirpalpha antibody or antigen-binding fragment thereof, and use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011372817.3 | 2020-11-30 | ||
CN202011372817 | 2020-11-30 | ||
CN202011602742.3 | 2020-12-29 | ||
CN202011602742.3A CN115368455A (zh) | 2020-11-30 | 2020-12-29 | 一种靶向人SIRPα蛋白的特异性抗体及其应用 |
CN202110911478.X | 2021-08-10 | ||
CN202110911478.XA CN114773467B (zh) | 2020-11-30 | 2021-08-10 | 抗SIRPα抗体或其抗原结合片段及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022110922A1 true WO2022110922A1 (zh) | 2022-06-02 |
Family
ID=81755265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/113416 WO2022110922A1 (zh) | 2020-11-30 | 2021-08-19 | 抗SIRPα抗体或其抗原结合片段及应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240018255A1 (zh) |
EP (1) | EP4253416A1 (zh) |
JP (1) | JP2024501134A (zh) |
WO (1) | WO2022110922A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017178653A2 (en) | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
CN110325549A (zh) * | 2016-12-09 | 2019-10-11 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
WO2019226973A1 (en) * | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
CN110799536A (zh) * | 2017-05-16 | 2020-02-14 | 斯索恩生物制药有限公司 | 抗SIRPα抗体 |
CN111448210A (zh) * | 2017-07-26 | 2020-07-24 | 四十七公司 | 抗SIRP-α抗体及相关方法 |
CN111635458A (zh) * | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
CN111995682A (zh) * | 2020-08-21 | 2020-11-27 | 博奥信生物技术(南京)有限公司 | 抗人SIRPα单克隆抗体及其用途 |
-
2021
- 2021-08-19 US US18/254,941 patent/US20240018255A1/en active Pending
- 2021-08-19 EP EP21896427.8A patent/EP4253416A1/en active Pending
- 2021-08-19 WO PCT/CN2021/113416 patent/WO2022110922A1/zh active Application Filing
- 2021-08-19 JP JP2023532562A patent/JP2024501134A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017178653A2 (en) | 2016-04-14 | 2017-10-19 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
CN110325549A (zh) * | 2016-12-09 | 2019-10-11 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
CN110799536A (zh) * | 2017-05-16 | 2020-02-14 | 斯索恩生物制药有限公司 | 抗SIRPα抗体 |
CN111448210A (zh) * | 2017-07-26 | 2020-07-24 | 四十七公司 | 抗SIRP-α抗体及相关方法 |
WO2019226973A1 (en) * | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
CN111635458A (zh) * | 2020-03-20 | 2020-09-08 | 上海健信生物医药科技有限公司 | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 |
CN111995682A (zh) * | 2020-08-21 | 2020-11-27 | 博奥信生物技术(南京)有限公司 | 抗人SIRPα单克隆抗体及其用途 |
Non-Patent Citations (7)
Title |
---|
"Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells", NATURE IMMUNOLOGY, vol. 8, no. 12, December 2007 (2007-12-01) |
"Uniprot", Database accession no. G7PGS8 |
"UNIPROT", Database accession no. P78324 |
"Velcro'' Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein (SIRP alpha) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 20, 15 May 2015 (2015-05-15) |
"Velcro'' Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein(SIRP alpha) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 20, 15 May 2015 (2015-05-15) |
MABS, vol. 11, no. 6, 2019, pages 1036 |
VOETS ET AL., JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, 2019, pages 340 |
Also Published As
Publication number | Publication date |
---|---|
US20240018255A1 (en) | 2024-01-18 |
EP4253416A1 (en) | 2023-10-04 |
JP2024501134A (ja) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6983371B2 (ja) | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 | |
US20230012428A1 (en) | Bifunctional fusion protein and pharmaceutical use thereof | |
WO2019042119A1 (zh) | 抗人cd47抗体及其用途 | |
JP2021510141A (ja) | Igおよびitimドメインを持つt細胞免疫受容体(tigit)に対する抗体およびその使用 | |
CN113248618B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
WO2018219327A1 (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
AU2019218319A1 (en) | Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
WO2021170082A1 (zh) | 抗cd47/抗pd-l1抗体及其应用 | |
WO2019141268A1 (zh) | 抗4-1bb抗体、其抗原结合片段及其医药用途 | |
CN110678484B (zh) | 抗pd-l1/抗lag3双特异性抗体及其用途 | |
CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
WO2020108611A1 (zh) | 抗cd40抗体、其抗原结合片段及其医药用途 | |
WO2021013142A1 (zh) | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 | |
WO2020063660A1 (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
TW201904999A (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
WO2022095970A1 (zh) | 双特异抗体及其应用 | |
WO2022110922A1 (zh) | 抗SIRPα抗体或其抗原结合片段及应用 | |
KR20240021162A (ko) | Alpha 5 베타 1 인테그린 결합제 및 이의 용도 | |
JP2023536629A (ja) | Cd47結合性作用剤およびその使用 | |
WO2023231705A1 (zh) | 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用 | |
CN114773467B (zh) | 抗SIRPα抗体或其抗原结合片段及应用 | |
WO2024094159A1 (zh) | 靶向人源ror1的单域抗体 | |
WO2022262749A1 (zh) | 靶向pd1和/或ox40的特异性结合蛋白 | |
WO2024051804A1 (zh) | 抗ilt4抗体及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21896427 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023532562 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18254941 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023010436 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021896427 Country of ref document: EP Effective date: 20230630 |
|
ENP | Entry into the national phase |
Ref document number: 112023010436 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230529 |